Compare IPCA Labs with FDC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FDC - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FDC IPCA LABS/
FDC
 
P/E (TTM) x 24.4 23.7 103.1% View Chart
P/BV x 8.7 4.6 190.8% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   FDC
EQUITY SHARE DATA
    IPCA LABS
Mar-19
FDC
Mar-18
IPCA LABS/
FDC
5-Yr Chart
Click to enlarge
High Rs1,042319 326.6%   
Low Rs590164 359.8%   
Sales per share (Unadj.) Rs298.661.6 484.4%  
Earnings per share (Unadj.) Rs35.09.9 351.8%  
Cash flow per share (Unadj.) Rs49.412.0 413.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.173.2 337.7%  
Shares outstanding (eoy) m126.35174.40 72.4%   
Bonus/Rights/Conversions ESOSBB-  
Price / Sales ratio x2.73.9 69.8%   
Avg P/E ratio x23.324.3 96.1%  
P/CF ratio (eoy) x16.520.2 81.8%  
Price / Book Value ratio x3.33.3 100.1%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,10842,118 244.8%   
No. of employees `00013.45.5 243.0%   
Total wages/salary Rs m7,8742,167 363.4%   
Avg. sales/employee Rs Th2,807.01,943.7 144.4%   
Avg. wages/employee Rs Th585.8391.7 149.5%   
Avg. net profit/employee Rs Th329.0313.7 104.9%   
INCOME DATA
Net Sales Rs m37,73210,751 351.0%  
Other income Rs m577510 113.2%   
Total revenues Rs m38,30911,260 340.2%   
Gross profit Rs m6,9012,267 304.4%  
Depreciation Rs m1,824351 519.1%   
Interest Rs m18914 1,347.9%   
Profit before tax Rs m5,4652,411 226.6%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,042671 155.3%   
Profit after tax Rs m4,4221,735 254.9%  
Gross profit margin %18.321.1 86.7%  
Effective tax rate %19.127.8 68.5%   
Net profit margin %11.716.1 72.6%  
BALANCE SHEET DATA
Current assets Rs m23,7787,213 329.7%   
Current liabilities Rs m10,9752,104 521.7%   
Net working cap to sales %33.947.5 71.4%  
Current ratio x2.23.4 63.2%  
Inventory Days Days10454 190.4%  
Debtors Days Days6628 237.8%  
Net fixed assets Rs m20,3686,865 296.7%   
Share capital Rs m253175 144.2%   
"Free" reserves Rs m30,97112,586 246.1%   
Net worth Rs m31,22412,761 244.7%   
Long term debt Rs m1,4096 23,475.0%   
Total assets Rs m45,50715,041 302.5%  
Interest coverage x30.0173.2 17.3%   
Debt to equity ratio x00 9,594.2%  
Sales to assets ratio x0.80.7 116.0%   
Return on assets %10.111.6 87.1%  
Return on equity %14.213.6 104.2%  
Return on capital %17.319.0 91.4%  
Exports to sales %45.912.3 371.7%   
Imports to sales %16.60-   
Exports (fob) Rs m17,3081,327 1,304.4%   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,3081,889 916.4%   
Fx outflow Rs m6,2660-   
Net fx Rs m11,0421,889 584.6%   
CASH FLOW
From Operations Rs m4,9231,498 328.5%  
From Investments Rs m-1,563201 -777.3%  
From Financial Activity Rs m-1,832-1,694 108.1%  
Net Cashflow Rs m1,52810 14,832.0%  

Share Holding

Indian Promoters % 45.9 68.9 66.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.7 242.6%  
FIIs % 25.3 7.5 337.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 19.0 91.6%  
Shareholders   36,892 23,730 155.5%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

FDC LTD. Announces Quarterly Results (3QFY20); Net Profit Up 67.7% (Quarterly Result Update)

Feb 10, 2020 | Updated on Feb 10, 2020

For the quarter ended December 2019, FDC LTD. has posted a net profit of Rs 733 m (up 67.7% YoY). Sales on the other hand came in at Rs 3 bn (up 26.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (2QFY20); Net Profit Up 45.4% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 11, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS